Methylene blue for the treatment of septic shock

Pharmacotherapy

Volumn 30, Issue 7, 2010, Pages 702-715

  Paciullo, Christopher A ^a   Horner, Deanna McMahon ^b   Hatton, Kevin W ^c   Flynn, Jeremy D ^d  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d University of Kentucky   (United States)

Author keywords

Methylene blue; Sepsis; Septic shock; Vasodilatory shock; Vasopressor

Indexed keywords

METHYLENE BLUE; NITRIC OXIDE; PLACEBO; GUANYLATE CYCLASE;

CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; METHEMOGLOBINEMIA; NONHUMAN; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN DISCOLORATION; TREATMENT OUTCOME; URINE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EVALUATION STUDY; HEMODYNAMICS; LUNG; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SHOCK, SEPTIC; VASODILATATION;

CLINICAL TRIALS AS TOPIC; GUANYLATE CYCLASE; HEMODYNAMICS; HUMANS; LUNG; METHYLENE BLUE; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; VASODILATION;

EID: 77954132020     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.7.702     Document Type: Review

References (65)

1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea network. Am J Respir Crit Care Med 2003;168:165-72.
2. Todd SR, Turner KL, Moore FA. Civetta, Taylor and Kirby's critical care, 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2009.
3. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
5. Cobb JP, Danner RL. Nitric oxide and septic shock. JAMA 1996;275:1192-6.
6. Levy MM. Results of the surviving sepsis campaign. Presented at the 38th critical care conference of the Society of Critical Care Medicine, Nashville, TN, January 31-February 4, 2009.
7. Lorente JA, Landin L, Renes E, et al. Role of nitric oxide in the hemodynamic changes of sepsis. Crit Care Med 1993;21: 759-67. (Pubitemid 23139556)
8. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
9. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994;120:227-37.
10. Murad F. The 1996 Albert Lasker medical research awards: signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA 1996;276:1189-92.
11. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-18.
12. de Belder AJ, Radomski MW, Why HJ, et al. Nitric oxide synthase activities in human myocardium. Lancet 1993;341: 84-5.
13. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000;161: 1781-5. (Pubitemid 30418107)
14. Vallance P, Benjamin N, Collier J. The effect of endotheliumderived nitric oxide on ex vivo whole blood platelet aggregation in man. Eur J Clin Pharmacol 1992;42:37-41.
15. Evgenov OV, Bjertnaes LJ. Administration of methylene blue in human septic shock: renaissance of an old drug? Crit Care Med 2003;31:1601-2; author reply 2.
16. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-9. (Pubitemid 124006769)
17. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
18. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med 1999;34:646-56.
19. Patel PN. Methylene blue for management of ifosfamideinduced encephalopathy. Ann Pharmacother 2006;40:299-303.
20. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 1995;332:1239-40.
21. Marczin N, Ryan US, Catravas JD. Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exp Ther 1992;263:170-9.
22. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993;45: 367-74.
23. Keaney JF Jr, Puyana JC, Francis S, Loscalzo JF, Stamler JS, Loscalzo J. Methylene blue reverses endotoxin-induced hypotension. Circ Res 1994;74:1121-5.
24. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol 1981;59:150-6.
25. Del Duca D, Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg 2009;87:640-2.
26. DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II. Methylene blue: absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci 1972;61:1086-90.
27. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000;56:247-50.
28. Weissgerber AJ. Methylene blue for refractory hypotension: a case report. AANA J 2008;76:271-4.
29. Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J 1996;72: 612-14. (Pubitemid 26345364)
30. Zygun DA, Bradley PG, Menon DK. Effect of methylene blue on middle cerebral artery flow velocity in a patient with severe sepsis following clipping of a cerebral aneurysm. Neurocrit Care 2005;2:39-42.
31. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD. Methylene blue increases systemic vascular resistance in human septic shock: preliminary observations. Intensive Care Med 1992;18:309-11.
32. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-8.
33. Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care 1998;13:164-8.
34. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363-70.
35. Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 2002;30: 2271-7.
36. Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995;21: 1027-31.
37. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001;29:1860-7.
38. Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002;30:755-62. (Pubitemid 35469712)
39. Park BK, Shim TS, Lim CM, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med 2005;20:123-8.
40. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995;23:259-64.
41. Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res 1999;32:1505-13.
42. Heemskerk S, van Haren FM, Foudraine NA, et al. Short-term beneficial effects of methylene blue on kidney damage in septic shock patients. Intensive Care Med 2008;34:350-4.
43. Andresen M, Dougnac A, Hernandez G, et al. Inhibition of the nitric oxide pathway in refractory septic shock [in Spanish]. Rev Med Chil 1996;124:442-7.
44. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003;125:426-7.
45. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496-9.
46. Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol 1998;275:H1016-23.
47. Driscoll W, Thurin S, Carrion V, Steinhorn RH, Morin FC III. Effect of methylene blue on refractory neonatal hypotension. J Pediatr 1996;129:904-8. (Pubitemid 27500370)
48. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
49. Paya D, Gray GA, Stoclet JC. Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 1993;21:926-30. (Pubitemid 23160681)
50. Artigas A, Bernard GR, Carlet J, et al. The American-European consensus conference on ARDS, part 2: ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157: 1332-47.
51. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928-48.
52. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351:159-69.
53. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813-18.
54. Heemskerk S, Pickkers P, Bouw MP, et al. Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am Soc Nephrol 2006;1:853-62.
55. Kessler MR, Eide T, Humayun B, Poppers PJ. Spurious pulse oximeter desaturation with methylene blue injection. Anesthesiology 1986;65:435-6. (Pubitemid 16031811)
56. Bilgin H, Ozcan B, Bilgin T. Methemoglobinemia induced by methylene blue pertubation during laparoscopy. Acta Anaesthesiol Scand 1998;42:594-5. (Pubitemid 28218485)
57. McRobb CM, Holt DW. Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. J Extra Corpor Technol 2008;40:206-14.
58. Brewer GJ. Rediscovery of the susceptibility of G6PD deficient persons to methemoglobinemia from oxidant drugs, and to hemolysis from methylene blue. Am J Hematol 2007;82:87-8.
59. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
60. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
61. G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:1-12.
62. G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:13-20.
63. Vazquez-Torres A, Jones-Carson J, Mastroeni P, Ischiropoulos H, Fang FC. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on microbial killing by activated peritoneal macrophages in vitro. J Exp Med 2000;192:227-36.
64. Brown GC. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim Biophys Acta 2001;1504:46-57.
65. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219-23.